Vol. 4, Issue 1, Part A (2022)

Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, leading to debilitating symptoms, such as abdominal pain, diarrhea, weight loss, and fatigue. Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of CD. Anti-TNF agents, which block the action of TNF-α, have revolutionized the treatment of CD, providing significant clinical benefits. This review aims to explore the efficacy of anti-TNF agents in treating Crohn’s disease, focusing on clinical outcomes, mechanisms of action, and associated risks and limitations. The review highlights data from clinical trials, real-world studies, and long-term follow-ups to provide a comprehensive understanding of their therapeutic role.